These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 33749648

  • 1. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
    Ni R, Röjdner J, Voytenko L, Dyrks T, Thiele A, Marutle A, Nordberg A.
    J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
    [Abstract] [Full Text] [Related]

  • 2. ³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain.
    Marutle A, Gillberg PG, Bergfors A, Yu W, Ni R, Nennesmo I, Voytenko L, Nordberg A.
    J Neuroinflammation; 2013 Jul 23; 10():90. PubMed ID: 23880036
    [Abstract] [Full Text] [Related]

  • 3. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
    Rodriguez-Vieitez E, Ni R, Gulyás B, Tóth M, Häggkvist J, Halldin C, Voytenko L, Marutle A, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2015 Jun 23; 42(7):1119-32. PubMed ID: 25893384
    [Abstract] [Full Text] [Related]

  • 4. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.
    J Nucl Med; 2012 Jan 23; 53(1):37-46. PubMed ID: 22213821
    [Abstract] [Full Text] [Related]

  • 5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A.
    Brain; 2011 Jan 23; 134(Pt 1):301-17. PubMed ID: 21149866
    [Abstract] [Full Text] [Related]

  • 6. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
    Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A.
    Brain; 2013 Jul 23; 136(Pt 7):2217-27. PubMed ID: 23757761
    [Abstract] [Full Text] [Related]

  • 7. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O.
    Eur J Nucl Med Mol Imaging; 2011 Sep 23; 38(9):1702-14. PubMed ID: 21547601
    [Abstract] [Full Text] [Related]

  • 8. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.
    Brain; 2008 Jun 23; 131(Pt 6):1630-45. PubMed ID: 18339640
    [Abstract] [Full Text] [Related]

  • 9. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
    Rodriguez-Vieitez E, Kumar A, Malarte ML, Ioannou K, Rocha FM, Chiotis K.
    Methods Mol Biol; 2024 Jun 23; 2785():195-218. PubMed ID: 38427196
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE, Farrar G.
    Acta Neuropathol; 2020 Oct 23; 140(4):463-476. PubMed ID: 32772265
    [Abstract] [Full Text] [Related]

  • 12. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.
    Arch Neurol; 2009 Jan 23; 66(1):60-7. PubMed ID: 19139300
    [Abstract] [Full Text] [Related]

  • 13. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer.
    Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dinkelborg L, Dyrks T, Cappai R.
    Nucl Med Biol; 2012 Oct 23; 39(7):1042-8. PubMed ID: 22503458
    [Abstract] [Full Text] [Related]

  • 14. Multitracer Approach to Understanding the Complexity of Reactive Astrogliosis in Alzheimer's Brains.
    Fontana IC, Kumar A, Okamura N, Nordberg A.
    ACS Chem Neurosci; 2024 Jan 17; 15(2):328-336. PubMed ID: 38133820
    [Abstract] [Full Text] [Related]

  • 15. [18F]-florbetaben PET/CT Imaging in the Alzheimer's Disease Mouse Model APPswe/PS1dE9.
    Stenzel J, Rühlmann C, Lindner T, Polei S, Teipel S, Kurth J, Rominger A, Krause BJ, Vollmar B, Kuhla A.
    Curr Alzheimer Res; 2019 Jan 17; 16(1):49-55. PubMed ID: 30345916
    [Abstract] [Full Text] [Related]

  • 16. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
    Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ, Florbetaben Phase 3 Study Group.
    Alzheimers Dement; 2015 Aug 17; 11(8):964-74. PubMed ID: 25824567
    [Abstract] [Full Text] [Related]

  • 17. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M, Delker A, Rötzer C, Böning G, Carlsen J, Cyran C, Mille E, Gildehaus FJ, Cumming P, Baumann K, Steiner H, Haass C, Herms J, Bartenstein P, Rominger A.
    Neuroimage; 2014 Jan 01; 84():843-53. PubMed ID: 24055703
    [Abstract] [Full Text] [Related]

  • 18. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, Kraut MA, Ferrucci L, Mathis CA, Klunk WE, O'Brien RJ, Davatzikos C, Wong DF, Resnick SM.
    Acta Neuropathol; 2012 Dec 01; 124(6):823-31. PubMed ID: 22864813
    [Abstract] [Full Text] [Related]

  • 19. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
    Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, Higuchi M, Halldin C, Nordberg A.
    Alzheimers Res Ther; 2017 Dec 11; 9(1):96. PubMed ID: 29229003
    [Abstract] [Full Text] [Related]

  • 20. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.
    Neuroimage; 2010 Aug 15; 52(2):488-96. PubMed ID: 20385246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.